# A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

> **NCT07268040** · PHASE2 · RECRUITING · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Malignant Solid Tumors

## Interventions

- **DRUG:** SHR-7787 Injection
- **DRUG:** SHR-1316 Injection
- **DRUG:** SHR-4849 Injection
- **DRUG:** Etoposide injection
- **DRUG:** Carboplatin injection
- **DRUG:** Cisplatin injection
- **DRUG:** BP102 Injection

## Key facts

- **NCT ID:** NCT07268040
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-23
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07268040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07268040, "A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07268040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*